In Vivo Compound Efficacy Evaluation

In the drug development process, higher costs have exacerbated the need to determine much earlier in the process whether or not a preclinical drug development candidate is ready to go into clinical trials, and how to recognize the greatest value for such candidates.

Taconic offers the comprehensive in vivo compound profiling program EffiPRO™, a customized battery of pharmacological tests and disease models to:

• Assess the therapeutic efficacy of lead compounds and/or drug development candidates by analysing their effects on key physiological functions in animals
• Screen for potential side effects caused by the administration of such compounds at relevant doses
• Discover novel disease indications for such compounds that were not previously known, thus expanding the market potential of those drug candidates

Taconic’s multidisciplinary team of physiologists, behavioral scientists, immunologists, pharmacologists, biochemists, and molecular biologists works collaboratively under one roof to assess the effect of the test agents in the context of whole animal. Taconic’s scientists have extensive experiences performing efficacy studies for small molecule compounds, biologics, stem cell therapeutics and nanoparticles via various routes of administration.

We understand that the research needs for in vivo characterisation of potential therapeutic agents vary depending on the stage and specific goals of a drug discovery and development program. Taconic’s scientific experts work with our clients to custom-design each study to best meet our clients’ needs and to provide interpretive data analysis at the end of each study. Our collective expertise related to multiple therapeutic areas and the wealth of pharmacologically validated in vivo assays allow us to assess the effects of the compound related to various physiological systems.